Quality statement 13: Small‑cell lung cancer

Quality statement

People with small‑cell lung cancer have treatment initiated within 2 weeks of the pathological diagnosis.

Quality measure

Structure: Evidence of local arrangements and written clinical protocols to ensure that people with small‑cell lung cancer have treatment initiated within 2 weeks of the pathological diagnosis.

Process: Proportion of people with small‑cell lung cancer who have treatment initiated within 2 weeks of the pathological diagnosis.

Numerator – the number of people in the denominator who have treatment initiated within 2 weeks of the pathological diagnosis.

Denominator – the number of people with small‑cell lung cancer.

What the quality statement means for each audience

Service providers ensure that systems are in place for people with small‑cell lung cancer to have treatment initiated within 2 weeks of the pathological diagnosis.

Healthcare professionals initiate treatment for people with small‑cell lung cancer within 2 weeks of the pathological diagnosis.

Commissioners ensure they commission services for people with small‑cell lung cancer to have treatment initiated within 2 weeks of the pathological diagnosis.

People with small‑cell lung cancer have treatment started within 2 weeks of their diagnosis.

Source guidance

Lung cancer: diagnosis and management (2019) NICE guideline NG122, recommendation 1.4.52

Data source

Structure: Local data collection.

Process: Data fields necessary for the calculation of the interval between the date of tissue diagnosis and date of first chemotherapy treatment are available in the National Cancer Outcomes and Services dataset, which is available from the National Cancer Intelligence Network.

The Health and Social Care Information Centre National Lung Cancer Data Audit collects data on the proportion of small‑cell lung cancer patients submitted to the audit receiving treatment within a given timeframe.

Definitions

Treatment for small‑cell lung cancer is in accordance with the NICE guideline on lung cancer, recommendations 1.4.53–1.4.57 and 1.4.59–1.4.67, and NICE technology appraisal guidance on topotecan for the treatment of relapsed small-cell lung cancer.